Sanara MedTech Inc. Announces Exclusive License Agreement for Patented Collagen Peptides
- None.
- None.
The exclusive license agreement between Sanara MedTech Inc. and Tufts University to develop and commercialize patented collagen peptides represents a strategic move to strengthen Sanara's position in the bioactive collagen peptide market. Collagen peptides are increasingly used in medical applications due to their wound healing properties and potential to reduce healthcare costs by accelerating patient recovery. The formation of Sanara Collagen Peptides, LLC and the issuance of 10% of its outstanding units to Tufts aligns the interests of both parties, potentially accelerating the development process.
By securing rights to patents in multiple jurisdictions, Sanara is poised to tap into a broader market, including significant economies in Europe. The royalty rates of 1.5% to 3% are within the standard range for the industry and the minimum annual royalties indicate a commitment to generating sales and providing a revenue stream to Tufts. This collaboration could lead to innovative products that may capture a significant share of the market, which is beneficial for Sanara's growth prospects and could impact its stock valuation positively.
Analyzing the financial implications of the license agreement, the structured royalty payments suggest a manageable financial commitment for Sanara, with the potential for high returns if the new products gain market acceptance. The minimum annual royalty payments ensure a baseline income for Tufts, while incentivizing Sanara to maximize sales to offset these fixed costs. The commitment to research and development, as indicated by the CEO's statement, could lead to increased operational expenses in the short term. However, if successful, the long-term benefits include a diversified product line and potential market leadership in bioactive collagen peptides.
Investors should monitor the progress of product development and commercialization closely, as delays or failures could impact expected revenues. Conversely, successful product launches could significantly enhance earnings and shareholder value. The stock market typically reacts favorably to such strategic partnerships, especially when they involve patented technologies with the potential to disrupt existing markets or create new ones.
The medical significance of this agreement lies in the potential applications of the 18 unique collagen peptides covered by the patents. Collagen peptides have a variety of uses in regenerative medicine, from wound healing to tissue engineering. The focus on improving patient outcomes and reducing healthcare costs aligns with current medical industry trends towards value-based care. The expertise of Sanara's research and development team at Rochal could be pivotal in translating these patented peptides into clinically effective products.
It is crucial to assess the scientific validity and potential efficacy of these collagen peptides through rigorous clinical trials. The success of these products in clinical settings will ultimately determine their commercial success and impact on Sanara's business. The medical community's acceptance of these new applications will hinge on demonstrated improvements in patient care outcomes compared to current standards.
FORT WORTH, TX, Jan. 03, 2024 (GLOBE NEWSWIRE) -- Sanara MedTech Inc. Based in Fort Worth, Texas, Sanara MedTech Inc. (“Sanara,” the “Company,” “we,” “our” or “us”) (NASDAQ: SMTI), announced today that is has signed an exclusive license agreement with Tufts University (“Tufts”) to develop and commercialize patented technology covering 18 unique collagen peptides.
Zach Fleming, Sanara’s CEO stated, “Sanara has established itself as a leader in bioactive collagen peptides with CellerateRX® Surgical Powder (“CellerateRX”). We see significant opportunities to broaden our existing CellerateRX product line and develop new bioactive collagen peptide-based applications that will help improve outcomes and advance patient care while reducing healthcare system costs. We believe that the technology that we have licensed from Tufts, supported by the expertise of our research and development team at Rochal, can help us expand our product offering of collagen products.”
License Overview
- As part of this agreement, Sanara has formed a new subsidiary, Sanara Collagen Peptides, LLC (“SCP”), and has issued
10% of SCP’s outstanding units to Tufts. - SCP has exclusive rights to develop and commercialize new products based on the licensed patents and patents pending.
- The agreement includes one U.S. patent, one granted European patent (validated in France, Germany, Great Britain, and Switzerland/Liechtenstein), one Canadian patent pending, and one Patent Cooperation Treaty (“PCT”) patent pending.
- SCP will pay royalties to Tufts based on net sales of licensed products and technologies. Royalties will be calculated at a rate of
1.5% or3% , depending on the type of product or technology developed. - SCP will pay Tufts a minimum annual royalty of
$50,000 on January 1 of the year following the first anniversary of the first commercial sale of the licensed products or technologies. SCP will pay Tufts a$100,000 m inimum annual royalty on January 1 of each subsequent year during the royalty term specified in the exclusive license agreement.
About Sanara MedTech Inc.
Sanara MedTech Inc. is a medical technology company focused on developing and commercializing transformative technologies to improve clinical outcomes and reduce healthcare expenditures in the surgical, chronic wound and skincare markets. The Company markets, distributes and develops surgical, wound and skincare products for use by physicians and clinicians in hospitals, clinics and all post-acute care settings and offers wound care and dermatology virtual consultation services via telemedicine. Sanara’s products are primarily sold in the North American advanced wound care and surgical tissue repair markets. Sanara markets and distributes CellerateRX® Surgical Activated Collagen®, FORTIFY TRG® Tissue Repair Graft and FORTIFY FLOWABLE® Extracellular Matrix as well as a portfolio of advanced biologic products focusing on ACTIGEN™ Verified Inductive Bone Matrix, ALLOCYTE® Plus Advanced Viable Bone Matrix, BiFORM® Bioactive Moldable Matrix, TEXAGEN® Amniotic Membrane Allograft, and BIASURGE™ Advanced Surgical Solution to the surgical market. In addition, the following products are sold in the wound care market: BIAKŌS® Antimicrobial Skin and Wound Cleanser, BIAKŌS™ Antimicrobial Wound Gel, BIAKŌS® Antimicrobial Skin and Wound Irrigation Solution and HYCOL® Hydrolyzed Collagen. Sanara’s pipeline also contains potentially transformative product candidates for mitigation of opportunistic pathogens and biofilm, wound re-epithelialization and closure, necrotic tissue debridement and cell compatible substrates. The Company believes it has the ability to drive its pipeline from concept to preclinical and clinical development while meeting quality and regulatory requirements. Sanara is constantly seeking long-term strategic partnerships with a focus on products that improve outcomes at a lower overall cost. In addition, Sanara is actively seeking to expand within its six focus areas of wound and skin care for the acute, post-acute, and surgical markets.
Information about Forward-Looking Statements
The statements in this press release that do not constitute historical facts are “forward-looking statements,” within the meaning of and subject to the safe harbor created by the Private Securities Litigation Reform Act of 1995. These statements may be identified by terms such as “aims,” “anticipates,” “believes,” “contemplates,” “continue,” “could,” “estimates,” “expect,” “forecast,” “guidance,” “intend,” “may,” “plan,” “possible,” “potential,” “predicts,” “preliminary,” “projects,” “seeks,” “should,” “targets,” “will” or “would,” or the negatives of these terms, variations of these terms or other similar expressions. These forward-looking statements include, among others, statements regarding the ability to expand our product offering of collagen products and develop new collagen-based applications, the development of new products, the timing of commercialization of our products and the regulatory approval process. These items involve risks, contingencies and uncertainties such as the extent of product demand, market and customer acceptance, the effect of economic conditions, competition, pricing, uncertainties associated with the development and process for obtaining regulatory approval for new products, the ability to consummate and integrate acquisitions, and other risks, contingencies and uncertainties detailed in the Company’s SEC filings, which could cause the Company’s actual operating results, performance or business plans or prospects to differ materially from those expressed in, or implied by these statements.
All forward-looking statements speak only as of the date on which they are made, and the Company undertakes no obligation to revise any of these statements to reflect the future circumstances or the occurrence of unanticipated events, except as required by applicable securities laws.
Investor Contact:
Callon Nichols, Director of Investor Relations
713-826-0524
CNichols@sanaramedtech.com
SOURCE: Sanara MedTech Inc.
FAQ
What is the company name and ticker symbol of Sanara MedTech Inc.?
What is the exclusive license agreement with Tufts University about?
What is the new subsidiary formed by Sanara as part of the agreement?
What are the key components of the license agreement?
How will royalties be calculated and paid to Tufts?
